Atopic AsthmaPhase 1NCT00671593
Differential Gene Expression in Lung and Peripheral Blood After Inhaled Allergen Challenge
A Phase 1 study testing House Dust Mite and Diluent in people with Atopic Asthma and Healthy, run by John Sundy at 1 site in United States.
Trial summary
The purpose of this study is to identify the genes in important airway cells that are specifically expressed following inhalation of house dust mite allergen among study subjects with either allergic asthma or healthy normal phenotypes. Read more about this study
- Who is it for?
- Ages 18 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Atopic Asthma, Healthy
- What is being tested?
- House Dust Mite and Diluent
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- Oct 2006to Apr 2009
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Allergic asthmatic, or nonallergic nonasthmatic
- Willing/able to give informed consent \& adhere to visit/protocol schedules.
- Screening visit laboratory, C-Xray, EKG, results within normal limits
- Women of childbearing potential must have a negative serum pregnancy test
- Screening Pulmonary function testing above study criteria parameters
Who cannot join
- Systemic corticosteroid administration for asthma within the previous 90days
- Antibiotic administration within the previous 30 days.
- Viral respiratory infection within the previous 14 days.
- Allergen immunotherapy to House dust mite within the last 10 years
- History of severe asthma requiring intubation.
- Occupational exposure to hay or grain dust.
Show all 17Show fewer
- Significant exposure history to cigarette smoke
- Past or present history of allergen immunotherapy to within the last 10 yrs
- Underlying illnesses that may result in altered lung function
- Students or employees under direct supervision by protocol investigators are ineligible
- Subjects allergic to medications used (or potentially used) in the study will be excluded.
- Subjects using aspirin will be excluded
- Subjects who abuse alcohol or illicit substances will be excluded
- Medication use other than for asthma, allergies or contraception
- Other medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements
- Nursing mothers
- Other investigational medication within the last 30 days
Trial locations and contacts
1 site in 1 country.
United States1 site
Duke University Medical Center
Durham, North Carolina, 27710
About this study
Official title: Genetics of Environmental Asthma: Differential Gene Expression in the Lung and Peripheral Blood After Inhaled Allergen Challenge
The purpose of this study is to identify the genes in important airway cells that are specifically expressed following inhalation of house dust mite allergen among study subjects with either allergic asthma or healthy normal phenotypes. This approach is designed to identify novel genes associated with both asthma pathogenesis (differentially expressed in the exposure-response study) and asthma susceptibility (genetically associated with asthma in a linkage/association study) for drug targets.
Read the detailed description
The purpose of this study is to identify the genes in airway epithelial and BAL cells that are differentially expressed following inhalation of house dust mite allergen among study subjects with allergic asthma and normal phenotypes. This approach is designed to identify novel genes associated with both asthma pathogenesis (differentially expressed in the exposure-response study) and asthma susceptibility (genetically associated with asthma in a linkage/association study).
Patients with asthma and allergic rhinitis have long been known to have positive skin test responses to house dust. In the 1960's it was shown that the dust mite was the most important source of allergen in house dust. Techniques for growing dust mites in the laboratory enabled the preparation of dust mite allergen extracts. Identification of the major allergens of dust mite along with specific skin test methodology has resulted in standardized dust mite allergen extracts for diagnostic and therapeutic use. Numerous epidemiologic studies have demonstrated the importance of sensitization to dust mite as risk factors for asthma and allergic rhinitis symptoms.
Administration of dust mite by inhalation is considered investigational. However, numerous studies demonstrate the safety of allergen inhalation in well characterized subjects. A recent NHLBI/NIAID Workshop summarized evidence of the safety and utility of research bronchoprovocation and bronchoscopy studies in subjects with chronic airway diseases. Bronchoprovocation challenge has emerged as an important tool to understand the environmental factors involved in the asthmatic response. Airway hyperresponsiveness (AHR), an exaggerated bronchoconstrictor response to a variety of stimuli, is a prominent characteristic of asthma. Importantly, AHR to methacholine is correlated with symptoms and severity of disease. Although the mechanisms underlying AHR are poorly understood, it is believed to result, at least in part, from airway inflammation. Bronchoprovocation is a well-established method to detect and quantify AHR and to obtain insights into the mechanisms associated with this pathophysiologic entity. Increased airway response after allergen inhalation parallels the subsequent inflammatory reaction, suggesting that the allergen-induced inflammation has direct effects on mechanisms of airway responsiveness. Moreover, the techniques and applications of bronchoprovocation, both for testing nonspecific airway responsiveness and specific allergen challenge, have been well defined. Therefore it is evident that bronchoprovocation testing is considered useful and safe, and also likely to yield important insights into the pathogenesis of asthma.
Bronchoscopic airway sampling for investigational purposes has also yielded important insights regarding the pathogenesis of asthma and related airway disorders. Bronchoalveolar lavage (BAL) and endobronchial brush biopsies have emerged as the most widely used invasive research tools to assess inflammation and tissue remodeling in airway and interstitial lung diseases. Such procedures allow airway inflammatory and epithelial cells, proteins and other molecules of interest to be isolated in vivo in a manner that is critical to understanding the complex nature of asthma and other airway disorders. Numerous reports have attested to the safety of bronchoscopy including BAL and brush biopsy; these reports have been reviewed recently in a joint publication between the NHLBI and NIAID. So not only is bronchoscopic airway sampling important scientifically, but it is considered appropriate for research use in normal and asthmatic subjects.
The combination of bronchoprovocation and bronchoscopic airway sampling thus seems ideally suited to understand the complex host-environment interactions of asthma: the environmental stimulus response in a specified host could trigger a number of reactions that could be measured in the distal airways and airway epithelia.
- Conditions
- Atopic Asthma, Healthy
- Being tested
- House Dust Mite, Diluent
- Keywords
- Allergy, Asthma, healthy, Normal
- Medical subject headings
- Hypersensitivity, Asthma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
House Dust MiteBiological
Also called Allergen Extract Stand. Mite Dermatophagoides pteronyssinus
Dermatophagoides pteronyssinus: nebulized inhaled dosing is every 10 minutes per protocol limits at the following Allergen Concentration , (5 breaths of duration 0.8 seconds using a dosimeter) 0.0 AU, 0.3 AU/ml,
1 AU/ml, 3 AU/ml, 10 AU/ml, 30 AU/ml, 100 AU/ml, 300 AU/ml, 1000 AU/ml, 3000 AU/ml
DiluentBiological
Also called diluent(0.5% Nacl,0.25% NaHCO3,50% glycerin,& 0.4% phenol)
Greer lab allergen extract diluent (0.5% sodium chloride, 0.25% sodium bicarbonate, 50% glycerin (v/v), and 0.4% phenol)nebulized inhaled dosing is every 10 minutes per protocol limits at the following Diluent Concentration, (5 breaths of duration 0.8 seconds using a dosimeter)
| Study group | Role | What they receive |
|---|---|---|
| Experimental inhaled dust mite | Experimental | All subjects receive the same experimental inhaled challenge interventions Receives: Biological: House Dust Mite; Biological: Diluent |
What is being measured
The primary outcome is the main question the study is designed to answer.
Identify genes in airway epithelial and BAL cells that are differentially expressed following inhalation of house dust mite allergen among study subjects with allergic asthma and normal phenotypes.
Measured: 24 hours post challenge
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 May 2008 (estimated)
- Study startOct 2006
- Primary completionApr 2008
- Study completionApr 2009
Why it stopped: funding terminated
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atopic AsthmaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- John Sundy
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, John Sundy, Duke University
- Investigators
- John S Sundy, M.D., PhD., Principal investigator, Duke University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00671593
- Sponsor's protocol ID
- Pro00008369
- Other IDs
- 8874-07-8R1, 12496-CP-005
- Status last verified
- Jul 2013
- First submitted
- 2 May 2008
- Last updated
- 16 Jul 2013
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Genetics of Environmental Asthma: Differential Gene Expression in the Lung and Peripheral Blood After Inhaled Allergen Challenge
- ClinicalTrials.gov ID
- NCT00671593
- Acronym / sponsor ID
- Pro00008369
- Conditions
- Atopic Asthma, Healthy
- Keywords
- Allergy, Asthma, healthy, Normal
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: funding terminated
- Enrolment
- 40 participants (actual)
- Lead sponsor
- John SundyUniversity, hospital or other
- Study start
- Oct 2006
- Primary completion
- Apr 2008 (actual)
- Study completion
- Apr 2009 (actual)
- First posted
- 5 May 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to identify the genes in important airway cells that are specifically expressed following inhalation of house dust mite allergen among study subjects with either allergic asthma or healthy normal phenotypes. This approach is designed to identify novel genes associated with both asthma pathogenesis (differentially expressed in the exposure-response study) and asthma susceptibility (genetically associated with asthma in a linkage/association study) for drug targets.
Detailed description
The purpose of this study is to identify the genes in airway epithelial and BAL cells that are differentially expressed following inhalation of house dust mite allergen among study subjects with allergic asthma and normal phenotypes. This approach is designed to identify novel genes associated with both asthma pathogenesis (differentially expressed in the exposure-response study) and asthma susceptibility (genetically associated with asthma in a linkage/association study).
Patients with asthma and allergic rhinitis have long been known to have positive skin test responses to house dust. In the 1960's it was shown that the dust mite was the most important source of allergen in house dust. Techniques for growing dust mites in the laboratory enabled the preparation of dust mite allergen extracts. Identification of the major allergens of dust mite along with specific skin test methodology has resulted in standardized dust mite allergen extracts for diagnostic and therapeutic use. Numerous epidemiologic studies have demonstrated the importance of sensitization to dust mite as risk factors for asthma and allergic rhinitis symptoms.
Administration of dust mite by inhalation is considered investigational. However, numerous studies demonstrate the safety of allergen inhalation in well characterized subjects. A recent NHLBI/NIAID Workshop summarized evidence of the safety and utility of research bronchoprovocation and bronchoscopy studies in subjects with chronic airway diseases. Bronchoprovocation challenge has emerged as an important tool to understand the environmental factors involved in the asthmatic response. Airway hyperresponsiveness (AHR), an exaggerated bronchoconstrictor response to a variety of stimuli, is a prominent characteristic of asthma. Importantly, AHR to methacholine is correlated with symptoms and severity of disease. Although the mechanisms underlying AHR are poorly understood, it is believed to result, at least in part, from airway inflammation. Bronchoprovocation is a well-established method to detect and quantify AHR and to obtain insights into the mechanisms associated with this pathophysiologic entity. Increased airway response after allergen inhalation parallels the subsequent inflammatory reaction, suggesting that the allergen-induced inflammation has direct effects on mechanisms of airway responsiveness. Moreover, the techniques and applications of bronchoprovocation, both for testing nonspecific airway responsiveness and specific allergen challenge, have been well defined. Therefore it is evident that bronchoprovocation testing is considered useful and safe, and also likely to yield important insights into the pathogenesis of asthma.
Bronchoscopic airway sampling for investigational purposes has also yielded important insights regarding the pathogenesis of asthma and related airway disorders. Bronchoalveolar lavage (BAL) and endobronchial brush biopsies have emerged as the most widely used invasive research tools to assess inflammation and tissue remodeling in airway and interstitial lung diseases. Such procedures allow airway inflammatory and epithelial cells, proteins and other molecules of interest to be isolated in vivo in a manner that is critical to understanding the complex nature of asthma and other airway disorders. Numerous reports have attested to the safety of bronchoscopy including BAL and brush biopsy; these reports have been reviewed recently in a joint publication between the NHLBI and NIAID. So not only is bronchoscopic airway sampling important scientifically, but it is considered appropriate for research use in normal and asthmatic subjects.
The combination of bronchoprovocation and bronchoscopic airway sampling thus seems ideally suited to understand the complex host-environment interactions of asthma: the environmental stimulus response in a specified host could trigger a number of reactions that could be measured in the distal airways and airway epithelia.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Experimental inhaled dust mite | Experimental | Biological: House Dust Mite, Biological: DiluentAll subjects receive the same experimental inhaled challenge interventions |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Allergic asthmatic, or nonallergic nonasthmatic
- Willing/able to give informed consent \& adhere to visit/protocol schedules.
- Screening visit laboratory, C-Xray, EKG, results within normal limits
- Women of childbearing potential must have a negative serum pregnancy test
- Screening Pulmonary function testing above study criteria parameters
Key exclusion criteria (17 listed)
- Systemic corticosteroid administration for asthma within the previous 90days
- Antibiotic administration within the previous 30 days.
- Viral respiratory infection within the previous 14 days.
- Allergen immunotherapy to House dust mite within the last 10 years
- History of severe asthma requiring intubation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| House Dust MiteAlso: Allergen Extract Stand. Mite Dermatophagoides pteronyssinusDermatophagoides pteronyssinus: nebulized inhaled dosing is every 10 minutes per protocol limits at the following Allergen Concentration , (5 breaths of duration 0.8 seconds using a dosimeter) 0.0 AU, 0.3 AU/ml, 1 AU/ml, 3 AU/ml, 10 AU/ml, 30 AU/ml, 100 AU/ml, 300 AU/ml, 1000 AU/ml, 3000 AU/ml | Biological | Experimental inhaled dust mite |
| DiluentAlso: diluent(0.5% Nacl,0.25% NaHCO3,50% glycerin,& 0.4% phenol)Greer lab allergen extract diluent (0.5% sodium chloride, 0.25% sodium bicarbonate, 50% glycerin (v/v), and 0.4% phenol)nebulized inhaled dosing is every 10 minutes per protocol limits at the following Diluent Concentration, (5 breaths of duration 0.8 seconds using a dosimeter) | Biological | Experimental inhaled dust mite |
Primary outcome
Identify genes in airway epithelial and BAL cells that are differentially expressed following inhalation of house dust mite allergen among study subjects with allergic asthma and normal phenotypes.
Time frame: 24 hours post challenge
Results and safety
The study was stopped early (reason given: funding terminated). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2013.
Related trials for Atopic Asthma
RecruitingPhase 3
Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis_MM09-SIT-063.
Allergic Rhinitis, Allergic Rhinoconjunctivitis
RecruitingPhase 3
Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063.
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Enrolling by invitationObservational study
Allergy, Asthma, and Atopic Eczema in Finland
Asthma, Asthma in Children
RecruitingObservational study
NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)
Asthma
RecruitingObservational study
A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up
Allergy, Sinus Disorders, Atopic Diseases, Asthma, Allergic Rhinitis, Atopic Dermatitis, EoE, Drug a
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
John S Sundy, M.D., PhD. principal investigator
Duke University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing House Dust Mite and Diluent in people with Atopic Asthma and Healthy, run by John Sundy at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 16 Jul 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: funding terminated). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Identify genes in airway epithelial and BAL cells that are differentially expressed following inhalation of house dust mite allergen among study subjects with allergic asthma and normal phenotypes. (time frame: 24 hours post challenge). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2013.